A serious health alert has been issued: certain formulations of the common painkiller nimesulide are now banned, and over-the-counter cough syrup sales may be restricted. This is a direct response to serious concerns about public health.
The government has taken decisive action, prohibiting the manufacture, sale, and distribution of nimesulide in oral, immediate-release forms exceeding 100 mg. This decision stems from the assessment that these formulations pose a potential health risk, with safer alternatives readily available. The Ministry of Health and Family Welfare emphasized the necessity of this ban, citing the public interest as the primary driver. The specific formulations affected are those containing more than 100 mg of nimesulide in an immediate-release format.
Simultaneously, the Ministry is considering removing cough syrups from the list of over-the-counter medications. This draft notification aims to remove “syrups… for cough” from Schedule K, which currently exempts certain medicines from requiring a prescription. However, cough lozenges, pills, or tablets will remain on the list.
But here's where it gets controversial... This move follows tragic incidents, including the deaths of at least 22 children in Madhya Pradesh after consuming contaminated cough syrups. There have been other similar cases, such as one in Rajasthan, where children were given cough syrups not intended for them, leading to fatalities.
An expert committee, advised by the drug regulator, proposed the removal of cough syrups from the exemption list due to these recent events involving contaminated products. Stakeholders have been given 30 days to provide feedback on the draft notification before it is considered for implementation.
The ban on certain nimesulide formulations aligns with recommendations from the Indian Council of Medical Research (ICMR) after reviewing the drug's effects on adults. The expert committee under the apex drug regulator accepted these recommendations, which also included guidelines for prescribing the medicine. And this is the part most people miss... Nimesulide is known to potentially cause liver toxicity in some cases.
The ICMR also advised that nimesulide should only be used as a second-line treatment when other medications are ineffective or cannot be prescribed. Furthermore, the ICMR recommended against its use in pregnant or breastfeeding women and those planning pregnancy. Patients with kidney or liver impairments should also avoid nimesulide, and it should not be administered with other liver- or kidney-toxic drugs. The drug is already banned for children under the age of 12.
The committee has requested the ICMR to assess the drug's impact on different age groups, specifically those under 12, between 12 and 18 years, and those over 60.
What do you think? Do you agree with the government's actions, or do you have concerns about the impact on access to medication? Share your thoughts in the comments below!
